Literature DB >> 25978438

An Official ATS/AACN/ACCP/ESICM/SCCM Policy Statement: Responding to Requests for Potentially Inappropriate Treatments in Intensive Care Units.

Gabriel T Bosslet, Thaddeus M Pope, Gordon D Rubenfeld, Bernard Lo, Robert D Truog, Cynda H Rushton, J Randall Curtis, Dee W Ford, Molly Osborne, Cheryl Misak, David H Au, Elie Azoulay, Baruch Brody, Brenda G Fahy, Jesse B Hall, Jozef Kesecioglu, Alexander A Kon, Kathleen O Lindell, Douglas B White.   

Abstract

BACKGROUND: There is controversy about how to manage requests by patients or surrogates for treatments that clinicians believe should not be administered.
PURPOSE: This multisociety statement provides recommendations to prevent and manage intractable disagreements about the use of such treatments in intensive care units.
METHODS: The recommendations were developed using an iterative consensus process, including expert committee development and peer review by designated committees of each of the participating professional societies (American Thoracic Society, American Association for Critical Care Nurses, American College of Chest Physicians, European Society for Intensive Care Medicine, and Society of Critical Care). MAIN
RESULTS: The committee recommends: (1) Institutions should implement strategies to prevent intractable treatment conflicts, including proactive communication and early involvement of expert consultants. (2) The term "potentially inappropriate" should be used, rather than futile, to describe treatments that have at least some chance of accomplishing the effect sought by the patient, but clinicians believe that competing ethical considerations justify not providing them. Clinicians should explain and advocate for the treatment plan they believe is appropriate. Conflicts regarding potentially inappropriate treatments that remain intractable despite intensive communication and negotiation should be managed by a fair process of conflict resolution; this process should include hospital review, attempts to find a willing provider at another institution, and opportunity for external review of decisions. When time pressures make it infeasible to complete all steps of the conflict-resolution process and clinicians have a high degree of certainty that the requested treatment is outside accepted practice, they should seek procedural oversight to the extent allowed by the clinical situation and need not provide the requested treatment. (3) Use of the term "futile" should be restricted to the rare situations in which surrogates request interventions that simply cannot accomplish their intended physiologic goal. Clinicians should not provide futile interventions. (4) The medical profession should lead public engagement efforts and advocate for policies and legislation about when life-prolonging technologies should not be used.
CONCLUSIONS: The multisociety statement on responding to requests for potentially inappropriate treatments in intensive care units provides guidance for clinicians to prevent and manage disputes in patients with advanced critical illness.

Entities:  

Keywords:  conflict resolution; end-of-life care; ethics committees; futility; shared decision making

Mesh:

Year:  2015        PMID: 25978438     DOI: 10.1164/rccm.201505-0924ST

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  83 in total

1.  You Can't Get What You Want: Innovation for End-of-Life Communication in the Intensive Care Unit.

Authors:  Margaret L Schwarze; Toby C Campbell; Thomas V Cunningham; Douglas B White; Robert M Arnold
Journal:  Am J Respir Crit Care Med       Date:  2016-01-01       Impact factor: 21.405

2.  Medically Inappropriate or Futile Treatment: Deliberation and Justification.

Authors:  Cheryl J Misak; Douglas B White; Robert D Truog
Journal:  J Med Philos       Date:  2015-12-17

3.  Mandate to obtain consent for withholding nonbeneficial cardiopulmonary resuscitation is misguided.

Authors:  James Downar; Michael Warner; Robert Sibbald
Journal:  CMAJ       Date:  2016-01-04       Impact factor: 8.262

4.  How should clinicians respond to requests for potentially inappropriate treatment?

Authors:  Gabriel T Bosslet; Jozef Kesecioglu; Douglas B White
Journal:  Intensive Care Med       Date:  2016-01-13       Impact factor: 17.440

Review 5.  Neuropalliative care: Priorities to move the field forward.

Authors:  Claire J Creutzfeldt; Benzi Kluger; Adam G Kelly; Monica Lemmon; David Y Hwang; Nicholas B Galifianakis; Alan Carver; Maya Katz; J Randall Curtis; Robert G Holloway
Journal:  Neurology       Date:  2018-06-27       Impact factor: 9.910

6.  Explaining the Process of Determining Futility Increases Lay Public Acceptance.

Authors:  Kunal Bailoor; Thomas S Valley; Stephanie Kukora; Darin B Zahuranec
Journal:  Ann Am Thorac Soc       Date:  2019-06

7.  The Muddied Understanding of Brain Death.

Authors:  Mark J McDonald
Journal:  J Pediatr Intensive Care       Date:  2017-06-27

8.  Physician Orders for Life-Sustaining Treatment and Limiting Overtreatment at the End of Life.

Authors:  Robert D Truog; Terri R Fried
Journal:  JAMA       Date:  2020-03-10       Impact factor: 56.272

9.  Effects of a Multimodal Program Including Simulation on Job Strain Among Nurses Working in Intensive Care Units: A Randomized Clinical Trial.

Authors:  Radia El Khamali; Atika Mouaci; Sabine Valera; Marion Cano-Chervel; Camille Pinglis; Céline Sanz; Amel Allal; Valérie Attard; Julie Malardier; Magali Delfino; Fifina D'Anna; Pierre Rostini; Stéphan Aguilard; Karine Berthias; Béatrice Cresta; Frédéric Iride; Valérie Reynaud; Jérémie Suard; Wlady Syja; Cécile Vankiersbilck; Nicole Chevalier; Karen Inthavong; Jean-Marie Forel; Karine Baumstarck; Laurent Papazian
Journal:  JAMA       Date:  2018-11-20       Impact factor: 56.272

10.  Factors Associated with Physician Moral Distress Caring for Hospitalized Elderly Patients Needing a Surrogate Decision-maker: a Prospective Study.

Authors:  Lucia D Wocial; James E Slaven; Kianna Montz; Patrick O Monahan; Susan E Hickman; Christopher M Callahan; Paul R Helft; Greg A Sachs; Lev Inger; Emily S Burke; Alexia M Torke
Journal:  J Gen Intern Med       Date:  2020-02-24       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.